Apatinib (YN968D1) is a novel and high selectivity inhibitor of the vascular endothelial growth factor receptor-2 (VEGFR2) tyrosine kinase, which will block the downstream signal transduction of VEGFR2 at the cellular level.4 Apatinib exerts promising antitumoral effect in various tumors.5, 6, 7 As shown in a third-phase clinical trial, Apatinib has been proven to be a safe and effective drug in patients with advanced gastric cancer.8 However, the antitumoral effect of Apatinib in human osteosarcoma has never been reported. The gene discussed is KDR; the disease is osteosarcoma.